Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice.

MLA

Chinnasamy, Dhanalakshmi, et al. “Gene Therapy Using Genetically Modified Lymphocytes Targeting VEGFR-2 Inhibits the Growth of Vascularized Syngenic Tumors in Mice.” The Journal of Clinical Investigation, vol. 120, no. 11, Nov. 2010, pp. 3953–68. EBSCOhost, https://doi.org/10.1172/JCI43490.

APA

Chinnasamy, D., Yu, Z., Theoret, M. R., Zhao, Y., Shrimali, R. K., Morgan, R. A., Feldman, S. A., Restifo, N. P., & Rosenberg, S. A. (2010). Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. The Journal of Clinical Investigation, 120(11), 3953–3968. https://doi.org/10.1172/JCI43490

Chicago

Chinnasamy, Dhanalakshmi, Zhiya Yu, Marc R Theoret, Yangbing Zhao, Rajeev K Shrimali, Richard A Morgan, Steven A Feldman, Nicholas P Restifo, and Steven A Rosenberg. 2010. “Gene Therapy Using Genetically Modified Lymphocytes Targeting VEGFR-2 Inhibits the Growth of Vascularized Syngenic Tumors in Mice.” The Journal of Clinical Investigation 120 (11): 3953–68. doi:10.1172/JCI43490.